Effects of dexmedetomidine, propofol, sevoflurane and S-ketamine on the human metabolome: A randomised trial using nuclear magnetic resonance spectroscopy

dc.contributor.authorNummela Aleksi J
dc.contributor.authorLaaksonen Lauri T
dc.contributor.authorLaitio Timo T
dc.contributor.authorKallionpää RoosaE
dc.contributor.authorLångsjö Jaakko W
dc.contributor.authorScheinin Joonas M
dc.contributor.authorVahlberg Tero J
dc.contributor.authorKoskela Harri T
dc.contributor.authorAittomäki Viljami
dc.contributor.authorValli Katja J
dc.contributor.authorRevonsuo Antti
dc.contributor.authorNiemi Mikko
dc.contributor.authorPerola Markus
dc.contributor.authorScheinin Harry
dc.contributor.organizationfi=PET-keskus|en=Turku PET Centre|
dc.contributor.organizationfi=anestesiologia ja tehohoito|en=Anaesthesiology, Intensive Care|
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=biostatistiikka|en=Biostatistics|
dc.contributor.organizationfi=psykologia|en=Psychology|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.14646305228
dc.contributor.organization-code1.2.246.10.2458963.20.15586825505
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.contributor.organization-code1.2.246.10.2458963.20.82197219338
dc.contributor.organization-code1.2.246.10.2458963.20.89365200099
dc.contributor.organization-code2607301
dc.converis.publication-id68445655
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/68445655
dc.date.accessioned2025-08-27T23:41:48Z
dc.date.available2025-08-27T23:41:48Z
dc.description.abstract<p><strong>Background: </strong>Pharmacometabolomics uses large-scale data capturing methods to uncover drug-induced shifts in the metabolic profile. The specific effects of anaesthetics on the human metabolome are largely unknown.</p><p><strong>Objective: </strong>We aimed to discover whether exposure to routinely used anaesthetics have an acute effect on the human metabolic profile.</p><p><strong>Design: </strong>Randomised, open-label, controlled, parallel group, phase IV clinical drug trial.</p><p><strong>Setting: </strong>The study was conducted at Turku PET Centre, University of Turku, Finland, 2016 to 2017.</p><p><strong>Participants: </strong>One hundred and sixty healthy male volunteers were recruited. The metabolomic data of 159 were evaluable.</p><p><strong>Interventions: </strong>Volunteers were randomised to receive a 1-h exposure to equipotent doses (EC50 for verbal command) of dexmedetomidine (1.5 ng ml-1; n = 40), propofol (1.7 μg ml-1; n = 40), sevoflurane (0.9% end-tidal; n = 39), S-ketamine (0.75 μg ml-1; n = 20) or placebo (n = 20).</p><p><strong>Main outcome measures: </strong>Metabolite subgroups of apolipoproteins and lipoproteins, cholesterol, glycerides and phospholipids, fatty acids, glycolysis, amino acids, ketone bodies, creatinine and albumin and the inflammatory marker GlycA, were analysed with nuclear magnetic resonance spectroscopy from arterial blood samples collected at baseline, after anaesthetic administration and 70 min postanaesthesia.</p><p><strong>Results: </strong>All metabolite subgroups were affected. Statistically significant changes vs. placebo were observed in 11.0, 41.3, 0.65 and 3.9% of the 155 analytes in the dexmedetomidine, propofol, sevoflurane and S-ketamine groups, respectively. Dexmedetomidine increased glucose, decreased ketone bodies and affected lipoproteins and apolipoproteins. Propofol altered lipoproteins, fatty acids, glycerides and phospholipids and slightly increased inflammatory marker glycoprotein acetylation. Sevoflurane was relatively inert. S-ketamine increased glucose and lactate, whereas branched chain amino acids and tyrosine decreased.</p><p><strong>Conclusion: </strong>A 1-h exposure to moderate doses of routinely used anaesthetics led to significant and characteristic alterations in the metabolic profile. Dexmedetomidine-induced alterations mirror α2-adrenoceptor agonism. Propofol emulsion altered the lipid profile. The inertness of sevoflurane might prove useful in vulnerable patients. S-ketamine induced amino acid alterations might be linked to its suggested antidepressive properties.</p>
dc.format.pagerange521
dc.format.pagerange532
dc.identifier.eissn1365-2346
dc.identifier.jour-issn0265-0215
dc.identifier.olddbid204440
dc.identifier.oldhandle10024/187467
dc.identifier.urihttps://www.utupub.fi/handle/11111/52687
dc.identifier.urlhttps://journals.lww.com/ejanaesthesiology/Fulltext/2022/06000/Effects_of_dexmedetomidine,_propofol,_sevoflurane.5.aspx
dc.identifier.urnURN:NBN:fi-fe2023050440820
dc.language.isoen
dc.okm.affiliatedauthorNummela, Aleksi
dc.okm.affiliatedauthorLaaksonen, Lauri
dc.okm.affiliatedauthorLaitio, Timo
dc.okm.affiliatedauthorKallionpää, Roosa
dc.okm.affiliatedauthorLångsjö, Jaakko
dc.okm.affiliatedauthorScheinin, Joonas
dc.okm.affiliatedauthorVahlberg, Tero
dc.okm.affiliatedauthorValli, Katja
dc.okm.affiliatedauthorRevonsuo, Antti
dc.okm.affiliatedauthorScheinin, Harry
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3126 Surgery, anesthesiology, intensive care, radiologyen_GB
dc.okm.discipline3126 Kirurgia, anestesiologia, tehohoito, radiologiafi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherWolters Kluwer
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.doi10.1097/EJA.0000000000001591
dc.relation.ispartofjournalEuropean Journal of Anaesthesiology
dc.relation.issue6
dc.relation.volume39
dc.source.identifierhttps://www.utupub.fi/handle/10024/187467
dc.titleEffects of dexmedetomidine, propofol, sevoflurane and S-ketamine on the human metabolome: A randomised trial using nuclear magnetic resonance spectroscopy
dc.year.issued2022

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
Effects_of_dexmedetomidine,_propofol,_sevoflurane.5.pdf
Size:
1.51 MB
Format:
Adobe Portable Document Format